Data from ESLIM-01 study assessing sovleplenib vs PBO in treatment-experienced primary ITP Chinese patients (n=188) in The Lancet Haematology & anticipates a dose-finding study in the US. Data also supported NDA submitted with the NMPA in Jan 2024
The study showed a sustained durable platelet response with DRR of 48.4% (61/126) vs 0%, ORR of 68.3% & 14.5% (12wks.) vs 70.6% & 16.1% (24wks.) & median time to response of 8 days vs 30 days
The post-hoc analysis depicted benefits of sovleplenib among ITP patients, irrespective of prior therapies or TPO/TPO-RA treatment, with a DRR of 47.7% vs 0% in patients with ≥4 prior therapies & 46.8% vs 0% in sovleplenib group previously treated with TPO/TPO-RA (74.6%)
Ref: HUTCHMED | Image: HUTCHMED
Related News:- HUTCHMED Reports NDA Acceptance with Priority Review by the NMPA for Sovleplenib to Treat Primary Immune Thrombocytopenia (PIT)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
